NO995942D0 - Mikrokrystallinsk cellulose: alginat-farmasöytiske suspensjoner - Google Patents

Mikrokrystallinsk cellulose: alginat-farmasöytiske suspensjoner

Info

Publication number
NO995942D0
NO995942D0 NO995942A NO995942A NO995942D0 NO 995942 D0 NO995942 D0 NO 995942D0 NO 995942 A NO995942 A NO 995942A NO 995942 A NO995942 A NO 995942A NO 995942 D0 NO995942 D0 NO 995942D0
Authority
NO
Norway
Prior art keywords
microcrystalline cellulose
alginate
pharmaceutical suspensions
suspensions
exemplified
Prior art date
Application number
NO995942A
Other languages
English (en)
Other versions
NO995942L (no
Inventor
Edward Selinger
John A Colliopoulos
Sheila M Dell
Jr William J Reilly
Original Assignee
Fmc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Corp filed Critical Fmc Corp
Publication of NO995942D0 publication Critical patent/NO995942D0/no
Publication of NO995942L publication Critical patent/NO995942L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO995942A 1997-06-04 1999-12-03 Mikrokrystallinsk cellulose: alginat-farmasøytiske suspensjoner NO995942L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/869,039 US5840768A (en) 1997-06-04 1997-06-04 MCC: alginate pharmaceutical suspensions
PCT/US1998/010961 WO1998055102A1 (en) 1997-06-04 1998-05-29 Microcrystalline cellulose: alginate pharmaceutical suspensions

Publications (2)

Publication Number Publication Date
NO995942D0 true NO995942D0 (no) 1999-12-03
NO995942L NO995942L (no) 2000-02-02

Family

ID=25352819

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995942A NO995942L (no) 1997-06-04 1999-12-03 Mikrokrystallinsk cellulose: alginat-farmasøytiske suspensjoner

Country Status (13)

Country Link
US (1) US5840768A (no)
EP (1) EP0998266B1 (no)
JP (1) JP2002511079A (no)
CN (1) CN1158992C (no)
AT (1) ATE250925T1 (no)
AU (1) AU737686B2 (no)
CA (1) CA2291719A1 (no)
DE (1) DE69818669D1 (no)
IL (1) IL133209A (no)
NO (1) NO995942L (no)
TR (1) TR199902961T2 (no)
TW (1) TW528604B (no)
WO (1) WO1998055102A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
WO2002010756A2 (en) * 2000-08-02 2002-02-07 Malope Company Limited Diagnosis and treatment of non-ulcer dyspepsia based on hypothalamic-pituitary-adrenal axis abnormality
US7300670B2 (en) * 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
CA2486553C (en) * 2002-06-17 2012-01-10 Taro Pharmaceuticals U.S.A., Inc. Ibuprofen suspension
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
CN101991531B (zh) * 2010-11-09 2012-06-27 武汉人福药业有限责任公司 布洛芬口服混悬液及其制备方法
CN102921038B (zh) * 2012-08-06 2014-07-09 西南交通大学 制备具有形状记忆功能的多孔支架的方法
CN114650401A (zh) 2020-12-21 2022-06-21 中强光电股份有限公司 投影装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263334A (en) * 1978-05-31 1981-04-21 Fmc Corporation Water dispersible cellulosic powder and method of making the same
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US5366742A (en) * 1993-05-03 1994-11-22 Fmc Corporation Colloidal microcrystalline cellulose and barrier dispersant composition and method for manufacture
US5605712A (en) * 1995-09-29 1997-02-25 Fmc Corporation Stabilizer compositions, frozen desserts containing the same and stabilizing method

Also Published As

Publication number Publication date
EP0998266A1 (en) 2000-05-10
TR199902961T2 (xx) 2000-06-21
WO1998055102A1 (en) 1998-12-10
EP0998266B1 (en) 2003-10-01
US5840768A (en) 1998-11-24
IL133209A0 (en) 2001-03-19
AU7703698A (en) 1998-12-21
AU737686B2 (en) 2001-08-30
ATE250925T1 (de) 2003-10-15
CN1278163A (zh) 2000-12-27
DE69818669D1 (de) 2003-11-06
CN1158992C (zh) 2004-07-28
NO995942L (no) 2000-02-02
JP2002511079A (ja) 2002-04-09
IL133209A (en) 2004-06-20
CA2291719A1 (en) 1998-12-10
TW528604B (en) 2003-04-21

Similar Documents

Publication Publication Date Title
DE69726179D1 (de) Pharmazeutische suspensionssysteme
DK1218374T3 (da) Farmaceutisk aktive sulfonamidderivater
EE200200060A (et) Moksifloksatsiini ja naatriumkloriidi sisaldav veepõhine preparaat
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
CA2376226A1 (en) New formulation
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
MY135119A (en) Stabilized oral suspension formulation
NO2011012I1 (no) Cimicoxib; 4[4-klor-5(3-fluor-4-metoksyfenyl)imidazol-1-yl]benzensulfonamid og farmasøytisk aksepterbare salter derav
EE05000B1 (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
NO995942D0 (no) Mikrokrystallinsk cellulose: alginat-farmasöytiske suspensjoner
AU5767900A (en) Monitorable three-dimensional scaffolds and tissue culture systems
HUP0103015A3 (en) Pharmaceutical suspension formulation comprising amoxycillin, clavulanic acid and cellulose
HRP20010878B1 (en) Ziprasidone suspension
TR200402419T4 (tr) Okskarbazepin içeren süspansiyon.
ATE262905T1 (de) Pharmazeutische formulierungen in hydroxypropylmethylcellulose-kapseln
RS50348B (sr) Farmaceutski oblik dronedarona za parenteralnu upotrebu
EP0717992A3 (en) Aqueous suspension formulations for pharmaceutical applications
HRP20010764B1 (en) Prucalopride oral solution
DE60026481D1 (de) Wässriges filmbildendes Überzugsmittel und oral anzuwendende feste Arzneizubereitung
DK1228041T3 (da) Indolderivater og anvendelse deraf som SHT2A-ligander
AU4165999A (en) Pesticide preparations in the form of aqueous suspension
HK1047104A1 (en) Spiroimidazolidine derivatives, their preparation,their use and pharmaceutical preparations compris ing them
WO1999066902A8 (en) Injectable pharmaceutical formulations of partricin derivatives
NO971604L (no) Orale sabeluzolsuspensjoner
PT1006148E (pt) Produto polissacarideo co-processado

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application